144 related articles for article (PubMed ID: 17896560)
1. [Photodynamic therapy in localised prostate cancer].
Ramírez Backhaus M; Trassierra Villa M; Vera Donoso CD; Jiménez Cruz JF
Actas Urol Esp; 2007 Jun; 31(6):633-41. PubMed ID: 17896560
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study.
Nathan TR; Whitelaw DE; Chang SC; Lees WR; Ripley PM; Payne H; Jones L; Parkinson MC; Emberton M; Gillams AR; Mundy AR; Bown SG
J Urol; 2002 Oct; 168(4 Pt 1):1427-32. PubMed ID: 12352410
[TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.
Moore CM; Emberton M; Bown SG
Lasers Surg Med; 2011 Sep; 43(7):768-75. PubMed ID: 22057504
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy for prostate cancer--a review of current status and future promise.
Moore CM; Pendse D; Emberton M
Nat Clin Pract Urol; 2009 Jan; 6(1):18-30. PubMed ID: 19132003
[TBL] [Abstract][Full Text] [Related]
5. Photosensitizers in prostate cancer therapy.
Gheewala T; Skwor T; Munirathinam G
Oncotarget; 2017 May; 8(18):30524-30538. PubMed ID: 28430624
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
7. [Local curative treatment of superficial adenocarcinoma in Barrett's esophagus. First results of photodynamic therapy with a new photosensitizer].
Etienne J; Dorme N; Bourg-Heckly G; Raimbert P; Fékété F
Bull Acad Natl Med; 2000; 184(8):1731-44; discussion 1744-7. PubMed ID: 11471391
[TBL] [Abstract][Full Text] [Related]
8. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
[TBL] [Abstract][Full Text] [Related]
9. Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.
Azzouzi AR; Vincendeau S; Barret E; Cicco A; Kleinclauss F; van der Poel HG; Stief CG; Rassweiler J; Salomon G; Solsona E; Alcaraz A; Tammela TT; Rosario DJ; Gomez-Veiga F; Ahlgren G; Benzaghou F; Gaillac B; Amzal B; Debruyne FM; Fromont G; Gratzke C; Emberton M;
Lancet Oncol; 2017 Feb; 18(2):181-191. PubMed ID: 28007457
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of photochemical internalisation using disulfonated chlorin and porphyrin photosensitisers: An in vitro study in 2D and 3D prostate cancer models.
Martinez de Pinillos Bayona A; Woodhams JH; Pye H; Hamoudi RA; Moore CM; MacRobert AJ
Cancer Lett; 2017 May; 393():68-75. PubMed ID: 28223166
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy for pancreatic cancer.
Fan BG; Andrén-Sandberg A
Pancreas; 2007 May; 34(4):385-9. PubMed ID: 17446835
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of 5-ALA mediated photodynamic therapy on hypoxic prostate cancer: a preclinical study on the Dunning R3327-AT2 rat tumor model.
Bozzini G; Colin P; Betrouni N; Maurage CA; Leroy X; Simonin S; Martin-Schmitt C; Villers A; Mordon S
Photodiagnosis Photodyn Ther; 2013 Sep; 10(3):296-303. PubMed ID: 23993856
[TBL] [Abstract][Full Text] [Related]
13. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
Azzouzi AR; Lebdai S; Benzaghou F; Stief C
World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in drug discovery of phototherapeutic non-porphyrinic anticancer agents.
Dichiara M; Prezzavento O; Marrazzo A; Pittalà V; Salerno L; Rescifina A; Amata E
Eur J Med Chem; 2017 Dec; 142():459-485. PubMed ID: 28943196
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy for prostate cancer - A narrative review.
Osuchowski M; Bartusik-Aebisher D; Osuchowski F; Aebisher D
Photodiagnosis Photodyn Ther; 2021 Mar; 33():102158. PubMed ID: 33352313
[TBL] [Abstract][Full Text] [Related]
16. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the in vitro and in vivo effects of photodynamic therapy on prostate cancer by using new photosensitizers, protoporphyrin IX-polyamine derivatives.
Fidanzi-Dugas C; Liagre B; Chemin G; Perraud A; Carrion C; Couquet CY; Granet R; Sol V; Léger DY
Biochim Biophys Acta Gen Subj; 2017 Jul; 1861(7):1676-1690. PubMed ID: 28188858
[TBL] [Abstract][Full Text] [Related]
18. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities.
Weersink RA; Bogaards A; Gertner M; Davidson SR; Zhang K; Netchev G; Trachtenberg J; Wilson BC
J Photochem Photobiol B; 2005 Jun; 79(3):211-22. PubMed ID: 15896648
[TBL] [Abstract][Full Text] [Related]
19. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker.
Plaks V; Koudinova N; Nevo U; Pinthus JH; Kanety H; Eshhar Z; Ramon J; Scherz A; Neeman M; Salomon Y
Neoplasia; 2004; 6(3):224-33. PubMed ID: 15153334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
